Leveraging PDX-derived Organoid (PDXO) Models for Combination Targeted Oncology

Time: 8:30 am
day: Day One


  • PDX-derived organoids are biologically equivalent to their matched PDX counterparts based on several shared characteristics
  • Screening of PDXO in a combination matrix approach enables rapid and valuable insight into combination strategies
  • A PDXO in vitro platform improves translatability of drug candidates, saves development time, and reduces animal usage by guiding optimal in vivo model selection for follow-on validation studies